Philips draws a line under its sleep nightmare
The group has finally revalued its troubled sleep franchise. So what now?
Asset resuscitation fails to resuscitate Mereo
Mereo claims another success with a big pharma castoff, but its win in alpha 1-antitrypsin deficiency is questionable.
Glaxo gets a Shingrix boost
But pressure is on the shingles vaccine as the consumer spin-off approaches.
